Key result
In ACS, high noradrenaline correlates with elevated glucose while high BNP links to lower glucose.
Why the study?
The compensatory actions of natriuretic peptides in collaboration with neurohumoral factors facilitating glucose utilization during ACS were unclear.
Observational (n=1,072)
No
BNP and noradrenaline coordinately activate glucose metabolism during acute coronary syndrome, with noradrenaline increasing glucose levels as an energy substrate while BNP improves insulin resistance.
Answers are grounded in this paper and cite their sources.
No immediate practice change in ACS; hypothesis-generating for neurohormonal glucose regulation and needs prospective validation.
Glucose is an important preferential substrate for energy metabolism during acute coronary syndrome (ACS) attack, although insulin resistance (IR) increases during ACS. Increasing evidence indicates that natriuretic peptides (NP) regulate glucose homeostasis. We investigated possible compensatory actions of NP in collaboration with other neurohumoral factors that facilitate glucose utilization during ACS. The study population consisted of 1072 consecutive cases with ischemic heart disease who underwent cardiac catheterization (ACS, n = 216; non-ACS, n = 856). Among ACS subjects, biochemical data after acute-phase treatment were available in 91 cases, defined as ACS-remission phase (ACS-rem). Path models based on covariance structure analyses were proposed to clarify the direct contribution of B-type NP (BNP) and noradrenaline to glucose and HOMA-IR levels while eliminating confounding biases. In non-ACS and ACS-rem subjects, although noradrenaline slightly increased glucose and/or HOMA-IR levels (P < 0.03), BNP did not significantly affect them. In contrast, in ACS subjects, high noradrenaline was a significant cause of increases in glucose and HOMA-IR levels (P < 0.001), whereas high BNP was a significant cause of decreases in both parameters (P < 0.005). These findings indicate that BNP and noradrenaline coordinately activate glucose metabolism during ACS, with noradrenaline increasing glucose levels, as an energy substrate, while BNP improves IR and promotes glucose utilization.
No takes yet. Share an insight, caveat, or question.
Uno et al. (2019) conducted an observational in Ischemic Heart Disease (Acute Coronary Syndrome) (n=1,072). Elevated noradrenaline and B-type natriuretic peptide (BNP) vs. Lower levels / Non-ACS subjects was evaluated on Direct contribution to plasma glucose levels in ACS subjects (Path model A) (β = -0.168 for BNP; β = 0.356 for noradrenaline, p=0.003 for BNP; <0.001 for noradrenaline). In patients with acute coronary syndrome, high noradrenaline levels significantly increased glucose levels, whereas high BNP levels significantly decreased glucose levels and improved insulin resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: